Diligence memo · auto-generated · as of July 2, 2026
Repros Therapeutics Inc.
Repros Therapeutics Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Repros Therapeutics Inc. operates in Biotechnology, based in WOODLANDS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Repros Therapeutics Inc. has raised $29M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $24M on 2012-09-07.
Most recent recorded round closed around 2012-09-07.
Valuation (modeled)modeled
Provath models Repros Therapeutics Inc. at approximately $937M (range $47M–$3.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.44× the median modeled value of Series B Biotechnology companies in 2010–2012 (48 peers) — value vs value, same stage and era. Within the normal band (144% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 34 months.
Last raise 13.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 74% of Biotechnology peers (4293 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Redpoint Bio CORP, Cardiaq Valve Technologies Inc, Visterra, Inc., Celltex Therapeutics Corp, Crown Bioscience, Inc.
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.